title: Predicting nonlinear changes in bone mineral density over time using a multiscale systems pharmacology model.
abstract: A mathematical model component that extends an existing physiologically based multiscale systems pharmacology model (MSPM) of calcium and bone homeostasis was developed, enabling prediction of nonlinear changes in lumbar spine bone mineral density (LSBMD). Data for denosumab, a monoclonal antibody osteoporosis treatment, dosed at several levels and regimens, was used for fitting the BMD component. Bone marker and LSBMD data extracted from the literature described on/off-treatment effects of denosumab over 48 months [Miller, P.D. et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43, 222-229 (2008)]. An indirect model linking bone markers to LSBMD was embedded in the existing MSPM, reasonably predicting nonlinear increases in LSBMD during treatment (24 months); LSBMD declines following discontinuation and increases upon treatment reinstitution. This study demonstrates the utility of MSPM extension to describe a phenomena of interest not originally in a model, and the ability of this updated MSPM to predict nonlinear longitudinal changes in the clinically relevant endpoint, LSBMD, with denosumab treatment.CPT: Pharmacometrics & Systems Pharmacology (2012) 1, e14; doi:10.1038/psp.2012.15; advance online publication 14 November 2012.
authors.affiliation: Pfizer, Pharmacometrics, Global Clinical Pharmacology, Cambridge, Massachusetts, USA.
authors.forename: M C
authors.initials: MC
authors.lastname: Peterson
authors.forename: M M
authors.initials: MM
authors.lastname: Riggs